MX353550B - Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro. - Google Patents

Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro.

Info

Publication number
MX353550B
MX353550B MX2014004457A MX2014004457A MX353550B MX 353550 B MX353550 B MX 353550B MX 2014004457 A MX2014004457 A MX 2014004457A MX 2014004457 A MX2014004457 A MX 2014004457A MX 353550 B MX353550 B MX 353550B
Authority
MX
Mexico
Prior art keywords
semaphorin
brain barrier
modulation
barrier permeability
binding molecules
Prior art date
Application number
MX2014004457A
Other languages
English (en)
Other versions
MX2014004457A (es
Inventor
S Smith Ernest
Zauderer Maurice
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of MX2014004457A publication Critical patent/MX2014004457A/es
Publication of MX353550B publication Critical patent/MX353550B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una cantidad eficaz de un anticuerpo aislado o fragmento del mismo que se une a antígeno, que se une específicamente a semaforina-4D (SEMA4D) para usarse como un medicamento para disminuir la permeabilidad de la barrera hematoencefálica (BBB) en un sujeto con permeabilidad BBB aumentada y un trastorno neuroinflamatorio, donde el anticuerpo o fragmento del mismo que se une a antígeno inhibe específicamente la interacción de semaforina 4D (SEMA4D) con el resceptor de SEMA4D, plexina B1.
MX2014004457A 2011-10-11 2012-10-11 Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro. MX353550B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161545809P 2011-10-11 2011-10-11
US201161555726P 2011-11-04 2011-11-04
US201261593641P 2012-02-01 2012-02-01
PCT/US2012/059757 WO2013055922A1 (en) 2011-10-11 2012-10-11 Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability

Publications (2)

Publication Number Publication Date
MX2014004457A MX2014004457A (es) 2014-06-05
MX353550B true MX353550B (es) 2018-01-18

Family

ID=48082436

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004457A MX353550B (es) 2011-10-11 2012-10-11 Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro.

Country Status (16)

Country Link
US (2) US20130095118A1 (es)
EP (1) EP2766093B1 (es)
JP (2) JP6395606B2 (es)
KR (1) KR101999872B1 (es)
CN (2) CN104168956A (es)
AU (1) AU2012322721B2 (es)
BR (1) BR112014008885B1 (es)
CA (1) CA2851805C (es)
DK (1) DK2766093T3 (es)
EA (1) EA029023B1 (es)
ES (1) ES2669209T3 (es)
IL (1) IL232072B (es)
MX (1) MX353550B (es)
PT (1) PT2766093T (es)
SG (1) SG11201401458UA (es)
WO (1) WO2013055922A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458468B (zh) 2009-05-08 2018-05-18 瓦西尼斯公司 抗-cd100抗体和其使用方法
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
KR20210104166A (ko) 2013-06-25 2021-08-24 백시넥스 인코포레이티드 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
NZ630881A (en) * 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) * 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
US10973930B2 (en) 2016-02-18 2021-04-13 The Penn State Research Foundation Generating GABAergic neurons in brains
EP3445397B1 (en) 2016-04-22 2022-11-09 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
CN109563143A (zh) 2016-08-02 2019-04-02 瓦西尼斯公司 在牛痘病毒/真核细胞中产生多核苷酸文库的改良方法
WO2018052948A1 (en) * 2016-09-13 2018-03-22 Angiocrine Bioscience, Inc. Blood-brain barrier comprising engineered endothelial cells
JP2020510845A (ja) * 2017-02-22 2020-04-09 バクシネックス インコーポレーティッド 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法
US11427634B2 (en) * 2017-05-05 2022-08-30 Vaccinex, Inc. Human anti-semaphorin 4D antibody
US20190092818A1 (en) * 2017-09-22 2019-03-28 Kite Pharma, Inc. Chimeric polypeptides and uses thereof
US20210032300A1 (en) * 2018-02-02 2021-02-04 The Penn State Research Foundation Methods and materials for treating brain injuries
AU2020211961A1 (en) * 2019-01-22 2021-09-09 Massachusetts Institute Of Technology In vitro human blood brain barrier
US20220220210A1 (en) * 2019-03-29 2022-07-14 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody-containing inhibitor for inhibiting deterioration of bbb function
US11597765B2 (en) 2020-06-25 2023-03-07 Vaccinex, Inc. Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
EP3973979A1 (en) * 2020-09-25 2022-03-30 The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth A tight junction (zonulae occludentes) protein for use in treating or preventing epilepsy
CN113456813A (zh) * 2021-07-26 2021-10-01 苏州大学 Semaphorin7A单克隆抗体在制备用于治疗血栓及脑血管疾病药物方面的应用
WO2023012314A1 (en) * 2021-08-05 2023-02-09 Lifearc Anti-plexin-b1 antibodies
CN114539204B (zh) * 2022-03-23 2023-08-22 福建金兰厚普生物科技有限公司 己糖激酶抑制剂及其合成方法和应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5070192A (en) 1988-03-23 1991-12-03 The Johns Hopkins University Cloned human topoisomerase i: cdna expression, and use for autoantibody detection
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
PT1325932E (pt) 1997-04-07 2005-06-30 Genentech Inc Anticorpos anti-vegf
JP2001516226A (ja) 1997-04-11 2001-09-25 デンドレオン コーポレイション 腫瘍関連性の抗原に対する免疫応答を誘導するための組成物および方法
EP0892047A3 (de) * 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6638501B1 (en) 1997-09-29 2003-10-28 Neurospheres Holdings Ltd. Use of multipotent neural stem cell progeny to augment non-neural tissues
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
DE69839970D1 (de) 1998-11-10 2008-10-16 Univ Rochester Methoden zu herstellung von genbanken
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP3787473B2 (ja) 1999-11-30 2006-06-21 独立行政法人科学技術振興機構 セマフォリン受容体
US6635742B1 (en) 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
AU2913801A (en) 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
CN1329060A (zh) 2000-06-19 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人semaphorin蛋白9和编码这种多肽的多核苷酸
DE60233509D1 (de) 2001-06-20 2009-10-08 Fibron Ltd Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20080219974A1 (en) 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
EP1365018A1 (en) 2002-05-23 2003-11-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) CD100 semaphorin in myelination
US7351803B2 (en) 2002-05-30 2008-04-01 Macrogenics, Inc. CD16A binding proteins and use for the treatment of immune disorders
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1442749A1 (en) 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
CN1788017B (zh) * 2003-02-10 2013-04-24 to-BBB控股股份有限公司 炎症状态下在血脑屏障中差异表达的核酸
KR20180014881A (ko) 2003-05-30 2018-02-09 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
CA2538763C (en) 2003-09-11 2015-05-05 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
AU2004296184B2 (en) 2003-12-04 2010-12-16 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
CA2548282A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
PL1773885T3 (pl) 2004-08-05 2010-09-30 Genentech Inc Humanizowani antagoniści anty c-met
US20060147449A1 (en) 2004-11-15 2006-07-06 Brass Lawrence F Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses
AU2006235271B2 (en) 2005-04-07 2011-05-19 Novartis Vaccines And Diagnostics Inc. SEMA4D in cancer diagnosis, detection and treatment
EP1952147A2 (en) 2005-11-16 2008-08-06 Novartis AG Biomarkers for anti-nogo-a antibody treatment in spinal cord injury
JP2007308465A (ja) 2006-05-15 2007-11-29 Boehringer Ingelheim Internatl Gmbh 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法
WO2008025020A2 (en) 2006-08-25 2008-02-28 Seattle Genetics, Inc. Cd30 binding agents and uses thereof
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
EP2436696B8 (en) * 2007-01-05 2017-12-13 University of Zurich Anti-beta-amyloid antibody and uses thereof
WO2008100995A1 (en) * 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
CA2678618C (en) 2007-02-21 2019-03-12 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cd1d molecules
AU2008341050B2 (en) 2007-12-26 2013-10-24 Vaccinex, Inc. Anti-C35 antibody combination therapies and methods
US20090181035A1 (en) 2008-01-10 2009-07-16 Genentech, Inc. Plexind1 agonists and their use
CN102458468B (zh) 2009-05-08 2018-05-18 瓦西尼斯公司 抗-cd100抗体和其使用方法
DK2429585T3 (en) 2009-05-15 2018-07-30 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY
JP5500944B2 (ja) 2009-10-29 2014-05-21 三菱電機株式会社 加熱調理器
US8834883B2 (en) 2010-06-14 2014-09-16 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
JP6097690B2 (ja) 2010-09-02 2017-03-15 ヴァクシネックス， インコーポレイテッド 抗ｃｘｃｌ１３抗体およびそれを用いる方法
DK2711023T3 (en) 2011-05-13 2017-10-16 Nat Univ Corp Tokyo Medical & Dental Univ osteogenesis
US8790652B2 (en) 2011-12-06 2014-07-29 Vaccinex, Inc. Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
KR102090969B1 (ko) 2012-03-02 2020-03-19 백시넥스 인코포레이티드 Ｂ 세포-매개 염증 질환의 치료 방법
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
KR102176962B1 (ko) 2013-01-31 2020-11-10 백시넥스 인코포레이티드 면역글로불린 a 수준을 증가시키기 위한 방법
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
KR20210104166A (ko) 2013-06-25 2021-08-24 백시넥스 인코포레이티드 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
EP3445397B1 (en) 2016-04-22 2022-11-09 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
CN109563143A (zh) 2016-08-02 2019-04-02 瓦西尼斯公司 在牛痘病毒/真核细胞中产生多核苷酸文库的改良方法
JP2020510845A (ja) 2017-02-22 2020-04-09 バクシネックス インコーポレーティッド 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法

Also Published As

Publication number Publication date
PT2766093T (pt) 2018-05-18
JP6395606B2 (ja) 2018-09-26
AU2012322721A1 (en) 2013-05-16
CA2851805A1 (en) 2013-04-18
IL232072B (en) 2021-01-31
KR101999872B1 (ko) 2019-07-12
JP2017193569A (ja) 2017-10-26
CN110105452A (zh) 2019-08-09
US11534488B2 (en) 2022-12-27
US20190358321A1 (en) 2019-11-28
DK2766093T3 (en) 2018-06-06
SG11201401458UA (en) 2014-07-30
US20130095118A1 (en) 2013-04-18
EP2766093A1 (en) 2014-08-20
WO2013055922A1 (en) 2013-04-18
CA2851805C (en) 2021-12-28
ES2669209T3 (es) 2018-05-24
EA029023B1 (ru) 2018-01-31
AU2012322721B2 (en) 2016-05-05
MX2014004457A (es) 2014-06-05
EP2766093B1 (en) 2018-02-21
JP2014530239A (ja) 2014-11-17
EP2766093A4 (en) 2015-03-25
IL232072A0 (en) 2014-05-28
EA201490768A1 (ru) 2014-09-30
BR112014008885B1 (pt) 2021-02-17
KR20140076616A (ko) 2014-06-20
BR112014008885A2 (pt) 2017-04-18
CN104168956A (zh) 2014-11-26
NZ623856A (en) 2016-04-29

Similar Documents

Publication Publication Date Title
MX353550B (es) Uso de moleculas de enlace a semaforina-4d para la modulacion de la permeabilidad de la barrera sangre-cerebro.
MX347164B (es) Anticuerpos anti-il-36r.
MY188469A (en) Low affinity blood brain barrier receptor antibodies and uses therefor
WO2012031250A8 (en) Compositions for labeling nerves and methods of use
PH12014502406B1 (en) Anti-il-23p19 antibodies
WO2011110642A3 (en) Monoclonal antibodies against c-met
MX2014008102A (es) Inmunoglobulinas de dominio variable dual contra receptores.
MX2021007663A (es) Molecula de union al antigeno especifico para el tejido objetivo.
MX347590B (es) Anticuerpos del cea.
EA201492067A1 (ru) Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсульта
MX2016004551A (es) Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis.
MX2013005015A (es) Anticuerpos anti-il-23.
UA115402C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
WO2014106001A3 (en) Dual specific binding proteins having a receptor sequence
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
MX2015005757A (es) Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
WO2012138708A8 (en) Mhc engagement and clip modulation for the treatment of disease
PH12015501980A1 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same
TN2014000207A1 (en) Anti il-36r antibodies
GB201019824D0 (en) Radioiodination method
TN2013000186A1 (en) Anti-il-23 antibodies

Legal Events

Date Code Title Description
FG Grant or registration